MYC and melanoma: For example, knocking down PP2A or PP2A inhibition by okadaic acid (OA) contributes to c-MYC stabilization, aberrant proliferation, and increased sensitivity to paclitaxel, doxorubicin and temozolomide in melanoma cells [111].